
Current status of FDA-approved cannabis or cannabis-derived compounds
There is much controversy regarding the use of marijuana for medical conditions and the regulations surrounding both cannabis and cannabidiol (CBD) products are both confusing and nuanced.
There is much controversy regarding the use of marijuana for medical conditions and the regulations surrounding both cannabis and cannabidiol (CBD) products are both confusing and nuanced.
As of this writing, cannabis and commercial CBD products have not been approved by the US Food and Drug Administration (FDA) for use in patients as they are concerned about safety and efficacy. Many state legislatures have sidestepped the FDA, permitting the use of marijuana and CBD for medical conditions with physician “approval.” There are now 33 legal “medical marijuana” states and Washington, DC; 10 legal recreational marijuana states and Washington, DC; and 17 states with “medical CBD” laws.
Last December, the Agricultural Improvement Act of 2018 was signed into law, which removed cannabis from the Controlled Substances Act. Previously, cannabis was a Schedule I drug, defined as drugs with no accepted medical use and high abuse potential, a category that includes heroin, ecstasy, peyote, and lysergic acid diethylamide (LSD). Congress, however, preserved the FDA’s authority to regulate cannabis and cannabis derivatives under the Federal Food Drug and Cosmetic Act and the Public Health Service Act.
In addition to Epidiolex, the CBD-only drug discussed in the article, the FDA has approved Marinol and Syndros, which contain the active ingredient dronabinol, a synthetic THC for treatment of anorexia associated with AIDS patients and nausea in adult and pediatric cancer patients who have not responded to antiemetics. Cesamet is another synthetic carbenoid, nabilone, with a structure similar to THC, and is FDA approved for treating nausea and vomiting associated with cancer chemotherapy in patients aged 18 years and older for whom other antiemetics are not effective. Sativex is an oromucosal spray contacting THC and CBD in a 1:1 ratio that is used overseas for treating pain associated with multiple sclerosis and is under consideration by the FDA for use in the United States.
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.



![Jodi Gilman, PhD, on cumulative prenatal adversity linked to adolescent mental health risk Document Jodi Gilman, PhD, on cumulative prenatal adversity linked to adolescent mental health risk Live? Do you want this document to be visible online? Scheduled Publishing Exclude From Home Page Do you want this document to be excluded from home page? Exclude From Infinite Scroll Do you want this document to be excluded from infinite scroll? Disable Related Content Remove related content from bottom of article. Password Protection? Do you want this gate this document? (If so, switch this on, set 'Live?' status on and specify password below.) Hide Comments [Experiment] Comments are visible by default. To hide them for this article toggle this switch to the on position. Show Social Share Buttons? Do you want this document to have the social share icons? Healthcare Professional Check Is Gated [DEV Only]Do you want to require login to view this? Password Password required to pass the gating above. Title Jodi Gilman, PhD, on cumulative prenatal adversity linked to adolescent mental health risk URL Unique identifier for this document. (Do not change after publishing) jodi-gilman-phd-on-cumulative-prenatal-adversity-linked-to-adolescent-mental-health-risk Canonical URL Canonical URL for this document. Publish Date Documents are usually sorted DESC using this field. NOTE: latency may cause article to publish a few minutes ahead of prepared time 2026-01-19 11:52 Updated On Add an updated date if the article has been updated after the initial publish date. e.g. 2026-01-19 11:50 Article Type News Display Label Author Jodi Gilman, Phd > Gilman, Jodi Author Fact Check Assign authors who fact checked the article. Morgan Ebert, Managing Editor > Ebert, Morgan Content Category Articles Content Placement News > Mental, Behavioral and Development Health > Clinical AD Targeting Group Put the value only when the document group is sold and require targeting enforcement. Type to search Document Group Mapping Now you can assign multiple document group to an article. No items Content Group Assign a content group to this document for ad targeting. Type to search Issue Association Please choose an issue to associate this document Type to search Issue Section Please choose a section/department head if it exists Type to search Filter Please choose a filter if required Type to search Page Number Keywords (SEO) Enter tag and press ENTER… Display summary on top of article? Do you want display summary on top of article? Summary Description for Google and other search engines; AI generated summary currently not supporting videos. Cumulative prenatal adversities were linked to higher adolescent mental health risk, highlighting the importance of prenatal history and early clinical monitoring. Abstract Body *********************************************************************************************************** Please include at least one image/figure in the article body for SEO and compliance purposes ***********************************************************************************************************](https://cdn.sanity.io/images/0vv8moc6/contpeds/e6097cb5e6d6c028c0d4e9efd069e69fdab6d00b-1200x628.png?w=350&fit=crop&auto=format)




